Home example 2 - Pharmamarketeer

onderzoek

Alexion phase 3 study of Ultomiris meets primary objective in complement inhibitornaïve patients with aHUS

Alexion Pharmaceuticals, Inc announced that the Phase 3 study of Ultomiris (ravulizumab?cwvz), the company’s long?acting C5 complement inhibitor, met its primary objective in complement inhibitor?

Pharma Biz

2 x gelezen

marketing

B2B Marketing Trendrapport 2019: 5 learnings op een rij

Op 20 juni 2019 heeft SRM Opleidingen en Spotler het B2B Marketing Trendrapport 2019 gelanceerd. Het B2B Marketing Trendrapport 2019 geeft inzicht in de uitdagingen, speerpunten en belangrijkste activiteiten van B2B...

MarketingTribune

2 x gelezen

wet- en regelgeving

Oxtellar XR Gains Monotherapy Indication for Partial-Onset Seizures

Supernus announced that the FDA has approved the supplemental New Drug Application for Oxtellar XR (oxcarbazepine) to include monotherapy use for the treatment of partial-onset seizures patients aged ≥6 years.

Monthly Prescribing Reference (MPR): Drug News

2 x gelezen

wet- en regelgeving

Dapagliflozine nuttig voor deel patiënten diabetes type 1

De Committee for Medicinal Products for Human Use (CHMP) beveelt de inzet van de SGLT-2-remmer dapagliflozine aan als eerste orale additionele therapie – naast insuline – voor bepaalde patiënten met diabetes mellitus...

Arts en Apotheker

2 x gelezen

overig

KNMP wil betere controle op productie geneesmiddelen

De controle op de productie van geneesmiddelen moet scherper en frequenter. Met name de controle op de productie buiten Europa moet beter, stelt voorzitter Gerben Klein Nulent van de apothekersorganisatie KNMP naar...

Skipr

2 x gelezen

overig

FDA refuses to review Celgene’s ozanimod in multple sclerosis

Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator ozanimod in the treatment of relapsing forms...

Pharmafile

2 x gelezen

wet- en regelgeving

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who...

News-Medical.Net

2 x gelezen

overig

De ultieme checklist voor de GDPR

Nu 2018 begonnen is, komt de deadline echt dichtbij. Vanaf 25 mei moeten alle organisaties zich houden aan de nieuwe privacywetgeving: de Algemene Verordening Gegevensbescherming (AVG / GDPR). Deze wet vervangt de...

marketingfacts.nl

2 x gelezen

technologie

Teleflex wins 2018 Medical Design Excellence Award for Arrow AC3 Optimus Intra-Aortic Balloon Pump

Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, is proud to announce the Arrow AC3 Optimus Intra-Aortic Balloon Pump, has been selected as the bronze winner in the...

News-Medical.Net

2 x gelezen

onderzoek

Researchers discover new genetic driver of autism and other developmental disorders

New genetic driver of autism A research group including Kobe University’s Professor TAKUMI Toru (also a Senior Visiting Scientist at RIKEN Center for Biosystems Dynamics Research) and Assistant Professor TAMADA...

News-Medical.Net

2 x gelezen

Latest articles

Alexion phase 3 study of Ultomiris meets primary objective in complement inhibitornaïve patients with aHUS

B2B Marketing Trendrapport 2019: 5 learnings op een rij

Oxtellar XR Gains Monotherapy Indication for Partial-Onset Seizures

Dapagliflozine nuttig voor deel patiënten diabetes type 1

KNMP wil betere controle op productie geneesmiddelen

FDA refuses to review Celgene’s ozanimod in multple sclerosis

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

De ultieme checklist voor de GDPR

Teleflex wins 2018 Medical Design Excellence Award for Arrow AC3 Optimus Intra-Aortic Balloon Pump

Researchers discover new genetic driver of autism and other developmental disorders

Wekelijkse highlights per e-mail

Algemene informatie